Fostamatinib: First Global Approval

Fostamatinib: First Global Approval Drugs https://doi.org/10.1007/s40265-018-0927-1 ADISINSIGHT REPORT Anthony Markham Springer International Publishing AG, part of Springer Nature 2018 Abstract Rigel Pharmaceuticals are developing the spleen in adult patients with chronic ITP who have had an tyrosine kinase (SYK) inhibitor fostamatinib (TAVA- insufficient response to a previous treatment [1]. Devel- TM LISSE ) as a treatment for immune thrombocytopenia opment of the drug in several further indications including (ITP), autoimmune haemolytic anaemia and IgA rheumatoid arthritis (RA), chronic lymphocytic leukae- nephropathy. Based on positive results in the phase III FIT mia, diffuse large B cell lymphoma, solid tumours and T clinical trial program, the drug was recently approved in cell lymphoma appears to have been suspended or dis- the US as a treatment for thrombocytopenia in adult continued. ITP is a bleeding disorder occurring as a result patients with chronic ITP who have had an insufficient of auto-immune destruction of platelets. Binding of anti- response to a previous treatment. This article summarizes platelet IgG antibodies to surface antigens renders plate- the milestones in the development of fostamatinib leading lets susceptible to SYK-dependent Fcc receptor (FccR)- to this first approval. mediated phagocytosis by macrophages. Inhibition of SYK disrupts this process, leading to improved platelet http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs Springer Journals

Fostamatinib: First Global Approval

Drugs , Volume OnlineFirst – Jun 4, 2018
Loading next page...
 
/lp/springer_journal/fostamatinib-first-global-approval-hBpVn4Jqh2
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
0012-6667
eISSN
1179-1950
D.O.I.
10.1007/s40265-018-0927-1
Publisher site
See Article on Publisher Site

Abstract

Drugs https://doi.org/10.1007/s40265-018-0927-1 ADISINSIGHT REPORT Anthony Markham Springer International Publishing AG, part of Springer Nature 2018 Abstract Rigel Pharmaceuticals are developing the spleen in adult patients with chronic ITP who have had an tyrosine kinase (SYK) inhibitor fostamatinib (TAVA- insufficient response to a previous treatment [1]. Devel- TM LISSE ) as a treatment for immune thrombocytopenia opment of the drug in several further indications including (ITP), autoimmune haemolytic anaemia and IgA rheumatoid arthritis (RA), chronic lymphocytic leukae- nephropathy. Based on positive results in the phase III FIT mia, diffuse large B cell lymphoma, solid tumours and T clinical trial program, the drug was recently approved in cell lymphoma appears to have been suspended or dis- the US as a treatment for thrombocytopenia in adult continued. ITP is a bleeding disorder occurring as a result patients with chronic ITP who have had an insufficient of auto-immune destruction of platelets. Binding of anti- response to a previous treatment. This article summarizes platelet IgG antibodies to surface antigens renders plate- the milestones in the development of fostamatinib leading lets susceptible to SYK-dependent Fcc receptor (FccR)- to this first approval. mediated phagocytosis by macrophages. Inhibition of SYK disrupts this process, leading to improved platelet

Journal

DrugsSpringer Journals

Published: Jun 4, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off